Teveten plus

Treatment option:

Medically reviewed

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Teveten plus

Property	Description
Active Ingredients	Eprosartan, Hydrochlorothiazide (HCTZ)
Form	Oral Tablet (film-coated)
Pharmacological Class	Angiotensin II Receptor Antagonist & Diuretic
Common Use	Management of High Blood Pressure
Origin	Synthetic (Prescription-Only Medicine)

Teveten plus: Identity and Classification as an Antihypertensive

Teveten plus is a prescription-only synthetic combination medicine utilized for the long-term systemic management of persistently high blood pressure, medically termed arterial hypertension. This formulation is classified as an Antihypertensive Agent, specifically falling into the category of Angiotensin II Receptor Antagonists and Diuretics. Unlike single-ingredient medications, the use of this dual-component approach is clinically recognized for its potential to achieve enhanced blood pressure lowering goals. This drug is primarily available under the brand names Teveten Plus and Teveten HCT.

Composition and Form: Eprosartan and Hydrochlorothiazide FDC

Teveten plus is a Fixed-Dose Combination (FDC) that contains two distinct active substances: Eprosartan and Hydrochlorothiazide (HCTZ), within a single tablet for oral administration. The dual composition includes Eprosartan, which is an ARB that helps relax blood vessels, and Hydrochlorothiazide, a Thiazide Diuretic that aids in reducing body fluid volume. This combination product is indicated when monotherapy with Eprosartan alone fails to adequately control a patient’s blood pressure. The FDC nature is specifically intended to simplify treatment, thereby supporting adherence to the prescribed regimen.

General Purpose of the Dual-Action Therapy

The general purpose of Teveten plus is to achieve effective, stable control of essential hypertension by simultaneously targeting both vascular tension and fluid volume. The therapy is employed for adult patients requiring intensified treatment to maintain optimal blood pressure. This dual-action strategy leverages established, complementary mechanisms, making it a comprehensive tool for the long-term management of chronic high blood pressure. This approach helps to ensure the continued management of elevated pressure, which is vital for long-term cardiovascular health.

Regulatory References

Combination Antihypertensive Therapy: ARB/HCTZ

What side effects are possible with Teveten plus?

Possible side effects and safety information

Regulatory Safety Restrictions

Official regulatory documents emphasize specific contraindications and a Black Box Warning regarding use during pregnancy. The medicine is contraindicated during the second and third trimesters of pregnancy due to significant risk of fetal injury and/or death; it must be discontinued immediately upon detection of pregnancy. It is also contraindicated in patients with anuria (inability to pass urine) or severe renal impairment, and in individuals with a known allergy to eprosartan, hydrochlorothiazide, or sulfonamide-derived drugs. Co-administration with aliskiren-containing medicines is contraindicated in patients with diabetes.

Common and Serious Adverse Reactions

Adverse reactions documented in clinical studies and post-marketing surveillance cover various system-organ classes. Common reactions (occurring in 1% or more of patients) may include headache, dizziness, fatigue, back pain, and upper respiratory tract infection.

Serious or clinically significant reactions have been documented. The hydrochlorothiazide component carries a risk of acute transient myopia and secondary angle-closure glaucoma, which can lead to permanent vision loss if untreated. Other rare but serious reactions include severe allergic (hypersensitivity) reactions like angioedema, renal dysfunction, hepatic dysfunction, and haematological disorders (e.g., agranulocytosis). Electrolyte imbalances, specifically hypokalemia (low potassium) and hyponatremia (low sodium), are potential effects of the diuretic component and require monitoring. The risk of certain types of skin cancer (non-melanoma) is also associated with long-term use of hydrochlorothiazide.

Overdose and Emergency Response

Overdose and when to seek help

The following information is derived strictly from government regulatory documentation for the fixed-dose combination of Eprosartan/Hydrochlorothiazide.

Overdose scope

Documented overdose presentations:

The most likely manifestation is hypotension (low blood pressure), accompanied by possible tachycardia or bradycardia.
Overdosage may cause excessive diuresis resulting in dehydration and severe electrolyte imbalances, including hypokalaemia and hyponatraemia.

Physiological systems affected (as stated in label):

Cardiovascular system, fluid and electrolyte balance, and the respiratory system (risk of Acute Respiratory Distress Syndrome).

Population-specific overdose notes (if applicable):

The effects of fluid and electrolyte depletion may precipitate hepatic coma in patients with severe hepatic impairment or azotaemia in those with impaired renal function.

Emergency-response statements (as written in official documents):

Treatment is symptomatic and supportive. This involves volume expansion and correction of fluid and electrolyte imbalances.
No specific antidote is known for overdosage.

When immediate medical help is required (label-derived phrasing only):

Seek immediate medical attention for any suspected overdosage.
Seek medical attention immediately if severe shortness of breath or difficulty breathing develops.

Overdose classifications (high-level)

Severity classification (as defined in official documents):

Overdosage carries the risk of marked hypotension and potentially life-threatening complications, such as cardiac arrhythmias or Acute Respiratory Distress Syndrome (ARDS).

Regulatory basis (EMA / FDA / etc.):

Information is derived from the approved regulatory prescribing documentation.

Overdose-context constraints (as defined in official documents):

Management must address the effects of both the Angiotensin II Receptor Antagonist and the Thiazide Diuretic components.

Resulting overdose structure

Official overdose statements:

The primary presentation is marked hypotension and severe fluid and electrolyte imbalance.
No specific antidote is known; therefore, treatment is symptomatic and supportive with a focus on volume and electrolyte correction.
Regulators mandate that patients seek immediate medical attention for suspected overdose or the onset of severe symptoms like difficulty breathing.

Connection to the overall overdose profile (2–4 sentences): Regulatory documents define the overdose profile of Teveten plus by requiring that management address the dual physiological risks of severe low blood pressure and critical fluid/electrolyte depletion. The official labeling mandates that patients seek immediate medical attention for suspected overdose and specifies that supportive care, including volume and electrolyte correction, is the required procedural instruction due to the absence of a known antidote. These official statements identify the circumstances and specific symptoms—such as difficulty breathing—that necessitate urgent medical help.

Therapeutic Uses of Teveten plus

What Teveten plus Treats: Main Uses and Benefits

Teveten plus is commonly used for the long-term, systemic management of essential hypertension (high blood pressure). It is applied to address the chronic condition of persistently elevated pressure by combining two complementary therapeutic actions. The primary benefit is relevant for easing both systolic and diastolic blood pressure, which is relevant for maintaining cardiovascular health.

This medication is generally used as a second-line treatment for adult patients whose blood pressure is not adequately controlled by eprosartan alone. It is applied when a patient may require additional management to meet blood pressure lowering goals. The combination may assist with managing blood pressure targets and is relevant for easing the long-term risk of severe complications, including heart disease, stroke, and kidney damage.

Indications include the management of essential hypertension when dual-agent therapy is appropriate, its use as a second-line treatment, and supporting high-risk cardiovascular patients, such as those with comorbid type 2 diabetes.

This fixed-dose combination supports adherence to the prescribed regimen, assisting with a more stable experience of day-to-day functioning.

Teveten plus may provide supportive benefit for high-risk individuals and those who require reliable and aggressive management of their elevated blood pressure, supporting long-term cardiovascular stability.

Quick Fact: Support for Persistent Systemic Strain This medication is applied in addressing the physiological strain and heightened physiological activity characteristic of chronic hypertension. It is relevant when supportive symptom management is appropriate for long-term health.

Regulatory References

European Medicines Agency (EMA) authorized information

Eligibility and Restrictions for Use

Who can and cannot use Teveten plus?

The population eligibility for Teveten plus is governed by specific regulatory criteria, primarily permitting use only in adult patients with essential hypertension.

Eligibility Status

Scope	Classification
Allowed	Adult patients with essential hypertension.
Not Recommended	Children and adolescents under 18 years; women in the 1st trimester of pregnancy or nursing women; patients with mild to moderate hepatic impairment.
Contraindicated	Patients with known allergy to eprosartan, hydrochlorothiazide, or sulfonamides; 2nd/3rd trimesters of pregnancy; severe renal impairment (CrCl < 30 mL/min) or anuria; severe hepatic impairment, cholestasis, or biliary obstructive disorders; therapy-resistant electrolyte disorders; or co-administration with aliskiren in diabetic/renal-impaired patients.

Population-Specific Rules

Age-Related: Use is not recommended in those under 18 years, as safety and efficacy have not been established in this pediatric population.
Organ Function: Use is contraindicated in severe liver disease and severe kidney disease. In mild to moderate hepatic impairment, use is not recommended.
Physiological Status: Use is contraindicated in later stages of pregnancy and not recommended during breastfeeding. Prior correction of severe sodium or volume depletion is required before initiating treatment.

The official eligibility profile is strictly defined by regulatory contraindications and restrictions based on patient population. Use is limited to adults who do not possess severe end-organ impairment or specific therapy-resistant metabolic conditions. The profile mandates absolute exclusion for high-risk groups, such as those in later pregnancy or with severe renal failure, establishing a clear boundary for authorized use.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Teveten plus (Eprosartan/Hydrochlorothiazide) is defined by officially documented effects on the Renin-Angiotensin System and electrolyte balance, as established by government regulatory bodies.

Interaction Relevance	Interacting Substances/Classes
Formally Contraindicated	Aliskiren in patients with diabetes mellitus.
Not Recommended	Lithium (due to reduced renal clearance leading to increased serum concentrations and toxicity) and dual blockade of the RAS with ACE-inhibitors or Aliskiren (due to risk of hyperkalaemia and reduced renal function).

Official regulatory documentation details several pharmacodynamic interactions that require specific consideration. Co-administration with NSAIDs (including COX-2 inhibitors) may attenuate the antihypertensive effect and increase the risk of worsening renal function, especially in the elderly. Combining with potassium-sparing diuretics or potassium supplements/salt substitutes is cautioned due to the additive risk of hyperkalaemia.

Furthermore, the profile indicates that Hydrochlorothiazide absorption is impaired by Cholestyramine and Colestipol resins. Conversely, Eprosartan is confirmed to be neutral regarding major CYP450 enzyme systems, as regulatory studies found it did not inhibit CYP1A, 2C9, 2D6, or 3A, simplifying its metabolic interaction context.

Mechanism of Action

Angiotensin II Receptor Blockade within the Renin-Angiotensin System

The eprosartan component acts within the renin-angiotensin-aldosterone system (RAAS). It acts by specifically blocking the binding of angiotensin II to the AT1 receptor, found in tissues like the smooth muscle of blood vessels. This receptor antagonism initiates a signaling sequence that suppresses the effects of Angiotensin II, primarily its vasoconstrictive action. This mechanism modifies early molecular steps that influence systemic vascular resistance and promotes vasodilation.

Inhibition of Tubular Ion Transport for Fluid and Electrolyte Regulation

The diuretic component, hydrochlorothiazide, engages mechanisms that regulate water and electrolyte movement across renal tubules. It acts by specifically inhibiting the sodium-chloride cotransporter (NCC) located in the distal convoluted tubule of the kidney. This action modifies the reabsorption of sodium and chloride, which results in increased urinary excretion of water and salt, and subsequently alters plasma volume.

Dosage and Administration Information

How to Use Teveten Plus: Administration Guidelines

This section outlines the usage instructions for Teveten Plus (eprosartan and hydrochlorothiazide) and is not a substitute for professional medical advice. Teveten Plus is an oral medication taken as a film-coated tablet.

Standard Dosing and Administration

Feature	Standard Instruction
Route of Administration	Oral (swallowing the tablet).
Standard Regimen	One tablet once daily.
Available Strengths	600 mg eprosartan / 12.5 mg hydrochlorothiazide; 600 mg eprosartan / 25 mg hydrochlorothiazide.
Intake Condition	May be taken with or without food.
Ingestion	The tablet must be swallowed whole with water.

Frequency and Missed Doses

Teveten Plus should be taken once daily, preferably at the same time each day (e.g., in the morning) to maintain a consistent effect. If a dose is missed, it should be taken as soon as remembered. However, if it is nearly time for the next scheduled dose, the missed dose should be skipped entirely, and the regular schedule resumed. Do not take a double dose to compensate for a missed one.

Population-Specific Constraints

Instructions mandate specific limitations based on patient health status:

Renal Impairment: The use of Teveten Plus is generally not recommended or contraindicated in patients with severe renal impairment (creatinine clearance < 30 ml/min) due to the hydrochlorothiazide component.
Hepatic Impairment: The drug is not recommended or contraindicated in patients with severe hepatic impairment. No dose adjustment is typically needed for the elderly or for those with mild to moderate impairment.
Pediatrics: Safety and effectiveness have not been established; therefore, Teveten Plus is not recommended for children and adolescents under 18 years of age.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Teveten plus contains a combination of eprosartan (an angiotensin II receptor antagonist) and hydrochlorothiazide (a thiazide diuretic). Clinical research has primarily focused on evaluating the combined effect of these two components in managing high blood pressure (essential hypertension).

Summary of Key Findings

Studies have investigated whether the combination therapy leads to greater changes in blood pressure compared to treatment with either eprosartan or hydrochlorothiazide alone. The evidence suggests that using the two agents together is associated with greater reductions in both systolic and diastolic blood pressure for patients whose condition is not adequately controlled by monotherapy.

Efficacy Trials

Short-term Trials: Double-blind randomized clinical trials (RCTs) typically lasting 8 to 12 weeks have compared the combination tablet against placebo and monotherapies. These studies observed that participants taking the combination reported significantly lower blood pressure readings than those on either component alone.
Long-term Observation: Open-label extension studies, lasting up to one year, have examined whether the reported blood pressure effects could be maintained over an extended period. These studies monitor the stability of blood pressure control with ongoing use.

Safety Profile in Research

Safety evaluations across clinical trials indicated that the combination was generally tolerated, with most reported side effects being mild and temporary. Adverse events reported during the trials included headache, dizziness, and fatigue. The safety profile has been examined in relation to the individual components, and studies also monitored specific risks associated with the components, such as changes in serum potassium levels (associated with the diuretic) or the potential for angioedema (associated with the eprosartan component).

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Teveten plus (FAQ)

Q: Is it common to have dizziness when first starting Teveten plus?

According to the official product information, dizziness is listed as a common adverse reaction, meaning it has been reported in 1% or more of patients during clinical studies. These effects are often related to the initial process of lowering blood pressure. Dizziness is a common reported side effect, and patients are typically advised to report any concerning symptoms to their healthcare provider.

Q: Can certain foods or drinks affect how Teveten plus works?

Official labeling indicates that Teveten plus tablets may be taken with or without food as the absorption of the active ingredients is not clinically affected by a meal. The drug's administration guidelines permit taking it based on convenience. Questions about specific drinks or foods are generally addressed by a qualified healthcare provider.

Q: Are there any major diet restrictions required when taking Teveten plus?

Regulatory documents caution against combining this medication with potassium supplements, potassium-sparing diuretics, or salt substitutes that contain potassium. This is due to the potential additive risk of developing hyperkalemia, which is an elevated level of potassium in the blood. Otherwise, no comprehensive, specific diet restrictions are mandated by the product labeling.

Q: Why do official documents mention fetal toxicity for Teveten plus?

The Eprosartan component works by blocking a system called the Renin-Angiotensin System (RAAS), which is vital for the development of the fetal kidneys. Exposure to the drug, especially during the second and third trimesters, can lead to severe fetal injury and death. For this reason, official product documents include a Black Box Warning regarding its use in pregnancy.

Q: Why is Teveten plus contraindicated during pregnancy?

The medicine is strictly contraindicated during the second and third trimesters of pregnancy due to the documented significant risk of fetal injury and/or death. Official warnings strongly advise that the medication be discontinued immediately upon detection of pregnancy, as it is a severe safety restriction based on regulatory requirements.

Q: How long does the effect of one dose of Teveten plus last?

Teveten plus is prescribed to be taken once daily, which is the regimen designed to provide consistent control of high blood pressure over a 24-hour period. Adherence to the prescribed administration schedule is necessary for effective blood pressure management.

Q: Is it normal to urinate more often when first starting this medication?

One of the active ingredients, hydrochlorothiazide, is a type of medicine known as a diuretic. Its primary function is to increase the excretion of salt and water by the kidneys. While regulatory documents do not list increased urination as an official side effect, the action of the diuretic component is specifically designed to promote the removal of excess fluid from the body.

Q: How quickly does Teveten plus typically start lowering blood pressure?

Clinical studies have examined the timeline for the drug’s effects on blood pressure. Evidence indicates that the maximum, most significant reduction in blood pressure is typically achieved after two to four weeks of beginning the prescribed treatment regimen. This means the full benefits of the medication may take a few weeks to become apparent.

Q: Is there a link between Teveten plus and muscle cramps?

Official adverse reaction lists categorize muscle pain, referred to medically as myalgia, as an uncommon reaction associated with the use of this medication. If muscle-related symptoms are a concern, a patient may choose to consult their prescribing clinician.

Q: Does taking Teveten plus make your skin more sensitive to the sun?

Official warnings state that the hydrochlorothiazide component is associated with a risk of photosensitivity reactions, which can make your skin more sensitive to sunlight or artificial UV light. Due to this association, monitoring of skin changes is generally noted in patient safety information.

Q: Is it true that Teveten plus can cause a cough?

Cough is not generally listed as a common side effect in the official adverse reaction data for this medication. This combination is in a class of drugs known as Angiotensin II Receptor Blockers (ARBs), which are often associated with a lower incidence of cough compared to some other types of blood pressure medications.

Q: Does Teveten plus affect blood sugar levels?

Regulatory warnings mention that the hydrochlorothiazide component may affect glucose tolerance in some individuals. Due to this potential effect on blood sugar, official documents indicate that monitoring of glucose levels may be necessary, particularly for patients who have diabetes.

Q: Does Teveten plus affect cholesterol levels?

The diuretic component, hydrochlorothiazide, has been described in regulatory warnings as potentially causing small increases in serum levels of certain lipids, including cholesterol and triglycerides. Changes to these levels are assessed as part of ongoing clinical management.

Q: Is Teveten plus a controlled substance?

Teveten plus is categorized as a prescription-only medicine and can only be obtained with a valid prescription from a healthcare provider. However, it is not listed as a controlled substance under government regulations.

Q: Can people with certain heart conditions use Teveten plus?

Official warnings and precautions state that use of this medication requires caution in patients who have certain heart conditions, such as coronary heart disease, heart failure, or narrowing of the heart valves. Eligibility is strictly determined by a healthcare provider after a complete evaluation of the patient's heart and vascular status.

Q: Does Teveten plus interact with alcohol?

Official product information notes that drinking alcohol while taking this medication may further enhance the blood pressure lowering effect. This potential effect is noted in the drug's interaction profile.

Q: Why is it important to avoid taking too much salt when on this drug?

The official warnings state that low blood volume or salt depletion (sodium depletion) must be corrected before treatment is started due to the risk of symptomatic low blood pressure (hypotension). The drug’s mechanism, which involves removing salt and water, makes proper fluid and salt balance a consideration for safe use.

Q: Can Teveten plus cause problems with sleeping?

Official regulatory data lists trouble sleeping, medically referred to as insomnia, as an uncommon adverse reaction. Persistent sleep issues are typically reviewed during follow-up appointments.

Q: Can I take cold and flu medicine while on Teveten plus?

Official interaction warnings specifically mention that combining this medication with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which are commonly found in cold and flu remedies, may increase the risk of worsening kidney function. Reviewing the compatibility of any over-the-counter medicine with a healthcare provider is generally recommended.

Q: Does Teveten plus affect libido or sexual function?

Official adverse reaction documents list impotence (erectile dysfunction) as an uncommon adverse reaction associated with this medication. Any experiences of this uncommon side effect are typically discussed with the prescribing physician.

How should Teveten plus be stored and disposed of?

How to Store and Dispose of Teveten Plus

Official regulatory labeling dictates specific conditions to maintain the stability and integrity of Teveten Plus tablets.

Storage Requirements

Teveten Plus must be stored at room temperature and kept from freezing. The required storage temperature is generally not above 25 C. To maintain product quality, the tablets must be protected from both moisture and excessive heat and should be kept in the original container. As a safety precaution, the medicine must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Teveten Plus must not be thrown away via wastewater or standard household waste. Proper disposal requires returning the product to a pharmacy or following designated local collection systems, in accordance with local requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.